Immunization with recombinant enterovirus 71 viral capsid protein 1 fragment stimulated antibody responses in hamsters
© Ch'ng et al.; licensee BioMed Central Ltd. 2012
Received: 25 November 2011
Accepted: 1 August 2012
Published: 9 August 2012
Enterovirus 71 (EV71) causes severe neurological diseases resulting in high mortality in young children worldwide. Development of an effective vaccine against EV71 infection is hampered by the lack of appropriate animal models for efficacy testing of candidate vaccines. Previously, we have successfully tested the immunogenicity and protectiveness of a candidate EV71 vaccine, containing recombinant Newcastle disease virus capsids that display an EV71 VP1 fragment (NPt-VP11-100) protein, in a mouse model of EV71 infection. A drawback of this system is its limited window of EV71 susceptibility period, 2 weeks after birth, leading to restricted options in the evaluation of optimal dosing regimens. To address this issue, we have assessed the NPt-VP11-100 candidate vaccine in a hamster system, which offers a 4-week susceptibility period to EV71 infection. Results obtained showed that the NPt-VP11-100 candidate vaccine stimulated excellent humoral immune response in the hamsters. Despite the high level of antibody production, they failed to neutralize EV71 viruses or protect vaccinated hamsters in viral challenge studies. Nevertheless, these findings have contributed towards a better understanding of the NPt-VP11-100 recombinant protein as a candidate vaccine in an alternative animal model system.
KeywordsEV71 Recombinant protein Hamster Immune response
The virion protein 1 (VP1) of EV71 was widely used in vaccine development using different delivery systems and shown to confer protection against lethal EV71 infection in mice [1, 2]. The N-terminal portion of the VP1 protein was suggested to contain a major antigenic site . It also preferentially bound by high-titered neutralizing antibodies to EV71 in human cord sera . Antigenic and neutralization determinants, which are important for vaccine development, are thus likely to be located in this region. Sivasamugham and colleagues (2006) developed and studied the first 100 amino acid residues of this N-terminal region of VP1 by fusing it to a carrier protein, a truncated nucleoprotein (NP) of Newcastle disease virus (NDV). This protein construct was designated as NPt-VP11-100 and found to be highly immunogenic in rabbit. The construct was also able to self-assemble into ring-like particles that could increase the VP11-100 immunogenicity. Rabbit sera generated after immunization was shown to recognize and react with the authentic EV71 . Altogether, these data suggest that the recombinant protein has great potential as a promising vaccine candidate against EV71 infections.
Recently, a mouse model with a prolonged susceptibility period to EV71 infections has been developed by Ong and colleagues . The susceptibility period was found to be up to 2-weeks after birth. This well-characterized mouse model infected by a mouse-adapted EV71 strain P5 (EV71P5) shared many characteristics with the human central nervous system (CNS) disease. To test the protective efficacy of the NPt-VP11-100 in this mouse model, we initially tested its immunogenicity in mice. It was found to be a potent immunogen in adult mice . Based on these information, we performed an extensive viral challenge studies in the above newborn mouse model. Newborn mice vaccinated with the NPt-VP11-100 showed more than 40 % increase in survival rate compared to the control group . Interestingly, 50 % of these mice fully recovered from their paralysis. Further analyses to improve the protective efficacy of the NPt-VP11-100 were hampered by the fact that the newborn mouse model can only provide a 2-week susceptibility period to EV71 infections . This narrow time window led to limitations in the testing of various parameters for vaccination and viral challenge. Previous study suggested that intervals between doses, age at priming and at the last dose of vaccination are factors that influence infant antibody responses . To address this issue, we needed an animal model which can offer a prolonged susceptibility period. It was observed that in newborn hamsters, EV71 virus was able to cause symptomatic infection for up to 4 weeks after birth (Prof. K.T. Wong, personal communication). Previously, Syrian hamsters were used to study Bulgarian strains of EV71 . The virus caused poliomyelitis-like lesions in their central nervous system, myositis and paralysis. In the present study, we evaluated the immunogenicity and protective efficacy of the EV71 NPt-VP11-100 candidate vaccine in a Syrian hamster model which offers a prolonged period of susceptibility to EV71 infection.
Initially, the full length NP (NPfl) and NPt-VP11-100 recombinant proteins were induced and purified as described previously [6, 7]. The EV71P5 was obtained from the Department of Pathology, Faculty of Medicine, Universiti Malaya, Malaysia . Purified VP1 protein of Enterovirus 71 was kindly provided by Prof. M.J. Cardosa of the Institute of Health and Community Medicine, Universiti Malaysia Sarawak .
Pregnant Syrian hamsters were purchased from the Animal House, Universiti Kebangsaan Malaysia. Animal experiments were done according to The Universiti Putra Malaysia Animal Care and Use Committee guidelines (AUP No: 10R84) and animals were cared for in accordance with The Code to Care and Use of Animals in Research. Newborn hamsters were immunized with three doses (10 μg per dose) of either NPfl (control group; n = 4) or NPt-VP11-100 (n = 5) proteins at 1-, 6- and 13-day old. The first dose containing 50 % Freund’s adjuvant (Sigma, USA) was injected subcutaneously, and subsequent doses containing Freund’s incomplete adjuvant (Sigma, USA) were injected intraperitoneally. On day 28 after birth, all the hamsters were challenged intraperitoneally with 2.53 x 106 TCID50 of EV71P5 virus. This viral dose was 4 times higher than the dose used in the mouse model study . Their body weight and paralysis score were monitored and recorded daily until day 12 post-challenge. The paralysis score was defined as: score 0, no hind limb paralysis and healthy; score 1, mild paralysis, weakness in hind limb(s); score 2, moderate paralysis, jerky movement; score 3, a hind limb shows severe paralysis; score 4, both hind limbs show severe paralysis. Their survival rate was monitored until the end of the experiment on day 18 post-challenge when they were sacrificed via cardiac puncture to collect their sera for further analysis. All the collected sera were subjected to an indirect enzyme-linked immunosorbent assay (ELISA) and immunoblotting analysis against purified full length VP1 and NPfl proteins as described previously [6, 7].
To test for potential EV71 neutralization properties of the antibodies produced, the sera were mixed with an equal volume of 100 TCID50 EV71 strain A104 virus and incubated at 37°C for 2 h. The resulting mixtures were assayed on Vero cells seeded in a 96-well plate as described in Ch'ng et al. . Cytopathic effects (CPE) were examined after 7 days of incubation and neutralization titers were determined as the highest dilutions that resulted in a 50 % inhibition of CPE. All the experimental data in this study were analysed using the Student's t-test and presented as mean ± standard error (SE). Differences with p <0.05 were considered significant.
The differences observed between the two animal systems were perhaps due to the use of the EV71P5 in the challenge studies. The mouse-adapted EV71P5 virus may not be suitable for the hamster model. It was noted that hamsters may only get severe infections and increased mortality when higher doses of virus, compared to the one in the present study, were used (unpublished observation). It is known that virus adaptation to a specific host will alter their infectivity to other hosts. Adaptation of EV71 clinical isolate in Chinese hamster ovary cells resulted in a reduced virulence in newborn BALB/c mice . Differences in genetic background of hosts are also important in viral infections . Receptor specificity is another factor which determines virus cell tropism . Hence, in the present study, the use of the mouse-adapted EV71P5 may contribute to the reduced susceptibility in the hamsters.
To further confirm the presence of anti-VP1 and anti-NP antibodies in all the collected sera, immunoblotting was performed. The sera were assayed against separated, purified full length VP1 and NPfl proteins. An intense band of about 40 kDa appeared on the VP1 membrane indicating positive detection for anti-VP1 antibodies (Figure 2C, arrow). As observed in the ELISA study, no band was noted in the pre-immune, as well as the pre-challenge sera from the control group. On the NPfl membrane, a band with approximate size of 55 kDa formed, confirming the presence of anti-NP antibodies (Figure 2C, arrowhead). The absence of a band in the pre-immune sera corroborated the previous ELISA findings. These results showed that the NPt-VP11-100 was capable of inducing high levels of immune responses in hamster. Overall, the immunogenicity of the protein is high in rabbit , mice  as well as hamsters.
Results obtained in this study showed that the NPt-VP11-100 candidate EV71 vaccine was capable of providing excellent immune stimulation in newborn hamsters. These data provide additional evidence that NPt-VP11-100 is a promising EV71 vaccine candidate. In addition, our findings also suggest that the hamster system may be used as an alternative animal model for the efficacy testing of EV71 candidate vaccines. Since the lack of appropriate animal models is one of the major hurdles for development of an effective vaccine towards EV71 infection, our findings will contribute towards the information needed for finding an optimum animal model. Importantly, the hamster system offers a prolonged susceptibility period to EV71 infection which allows for a more flexibility in parameter testing for vaccination and viral challenge. To improve this hamster system, we are currently optimizing several parameters such as the amount of proteins used in the vaccination, the immunization doses and intervals and the virus strain used in the challenge experiment. Nevertheless, these findings have paved ways towards a more comprehensive study of the evaluation of NPt-VP11-100 recombinant protein as a candidate EV71 vaccine in an alternative animal model system.
Virion protein 1
N-terminal region of VP1 containing 100 amino acid residues fused with a truncated NP of NDV
Full length NP
Central nervous system
Mouse-adapted EV71 strain P5
We thank W.T. Saw and J.Y. Lim for their technical assistance. This work was partially supported by the Malaysian Ministry of Science, Technology and Innovation grants 04-01-09-0802RU, 04-01-11-1159RU, 09-05-IFN-BPH-009 and 07-05-IFN-MEB006 and UM.C/625/1/HIR/MOHE/MED-06.
- Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS: Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001, 20: 895-904. 10.1016/S0264-410X(01)00385-1PubMedView ArticleGoogle Scholar
- Chiu CH, Chu C, He CC, Lin TY: Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect 2006, 8: 1671-1678. 10.1016/j.micinf.2006.01.021PubMedView ArticleGoogle Scholar
- Sivasamugham LA, Cardosa MJ, Tan WS, Yusoff K: Recombinant Newcastle Disease virus capsids displaying enterovirus 71 VP1 fragment induce a strong immune response in rabbits. J Med Virol 2006, 78: 1096-1104. 10.1002/jmv.20668PubMedView ArticleGoogle Scholar
- Tan CS, Cardosa MJ: High-titred neutralizing antibodies to human enterovirus 71 preferentially bind to the N-terminal portion of the capsid protein VP1. Arch Virol 2007, 152: 1069-1073. 10.1007/s00705-007-0941-1PubMedView ArticleGoogle Scholar
- Ong KC, Badmanathan M, Devi S, Leong KL, Cardosa MJ, Wong KT: Pathologic characterization of a murine model of human enterovirus 71 encephalomyelitis. J Neuropathol Exp Neurol 2008, 67: 532-542. 10.1097/NEN.0b013e31817713e7PubMedView ArticleGoogle Scholar
- Ch'ng WC, Saw WT, Yusoff K, Shafee N: Immunogenicity of a truncated enterovirus 71 VP1 protein fused to a Newcastle disease virus nucleocapsid protein fragment in mice. Acta Virol 2011, 55: 227-233. 10.4149/av_2011_03_227PubMedView ArticleGoogle Scholar
- Ch'ng WC, Stanbridge EJ, Ong KC, Wong KT, Yusoff K, Shafee N: Partial protection against enterovirus 71 (EV71) infection in a mouse model immunized with recombinant newcastle disease virus capsids displaying the EV71 VP1 fragment. J Med Virol 2011, 83: 1783-1791. 10.1002/jmv.22198PubMedView ArticleGoogle Scholar
- Siegrist CA: The challenges of vaccine responses in early life: selected examples. J Comp Pathol 2007,137(Suppl 1):S4-S9.PubMedView ArticleGoogle Scholar
- Chumakov M, Voroshilova M, Shindarov L, Lavrova I, Gracheva L, Koroleva G, Vasilenko S, Brodvarova I, Nikolova M, Gyurova S, et al.: Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol 1979, 60: 329-340. 10.1007/BF01317504PubMedView ArticleGoogle Scholar
- Chua BH, Phuektes P, Sanders SA, Nicholls PK, McMinn PC: The molecular basis of mouse adaptation by human enterovirus 71. J Gen Virol 2008, 89: 1622-1632. 10.1099/vir.0.83676-0PubMedView ArticleGoogle Scholar
- Srivastava B, Blazejewska P, Hessmann M, Bruder D, Geffers R, Mauel S, Gruber AD, Schughart K: Host genetic background strongly influences the response to influenza a virus infections. PLoS One 2009, 4: e4857. 10.1371/journal.pone.0004857PubMedPubMed CentralView ArticleGoogle Scholar
- Ibricevic A, Pekosz A, Walter MJ, Newby C, Battaile JT, Brown EG, Holtzman MJ, Brody SL: Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells. J Virol 2006, 80: 7469-7480. 10.1128/JVI.02677-05PubMedPubMed CentralView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.